{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:21:48Z","timestamp":1775578908698,"version":"3.50.1"},"reference-count":73,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathophysiology"],"abstract":"<jats:p>Limb girdle muscular dystrophy type R1 disease is a progressive disease that is caused by mutations in the CAPN3 gene and involves the extremity muscles of the hip and shoulder girdle. The CAPN3 protein has proteolytic and non-proteolytic properties. The functions of the CAPN3 protein that have been determined so far can be listed as remodeling and combining contractile proteins in the sarcomere with the substrates with which it interacts, controlling the Ca2+ flow in and out through the sarcoplasmic reticulum, and regulation of membrane repair and muscle regeneration. Even though there are several gene therapies, cellular therapies, and drug therapies, such as glucocorticoid treatment, AAV- mediated therapy, CRISPR-Cas9, induced pluripotent stem cells, MYO-029, and AMBMP, which are either in preclinical or clinical phases, or have been completed, there is no final cure. Inhibitors and small molecules (tauroursodeoxycholic acid, salubrinal, rapamycin, CDN1163, dwarf open reading frame) targeting ER stress factors that are thought to be effective in muscle loss can be considered potential therapy strategies. At present, little can be done to treat the progressive muscle wasting, loss of function, and premature mortality of patients with LGMDR1, and there is a pressing need for more research to develop potential therapies.<\/jats:p>","DOI":"10.3390\/pathophysiology28020016","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T23:34:46Z","timestamp":1621380886000},"page":"238-249","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Current and Future Therapeutic Strategies for Limb Girdle Muscular Dystrophy Type R1: Clinical and Experimental Approaches"],"prefix":"10.3390","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2105-4767","authenticated-orcid":false,"given":"\u0130zem Olcay","family":"\u015eahin","sequence":"first","affiliation":[{"name":"Department of Medical Genetics, Medical School, Erciyes University, 38039 Kayseri, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf","family":"\u00d6zkul","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Medical School, Erciyes University, 38039 Kayseri, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0969-4611","authenticated-orcid":false,"given":"Munis","family":"D\u00fcndar","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Medical School, Erciyes University, 38039 Kayseri, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/acn3.287","article-title":"Natural history of LGMD2A for delineating outcome measures in clinical trials","volume":"3","author":"Richard","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_2","unstructured":"(2020, October 20). OMIM\u2014Online Mendelian Inheritance in Man. Available online: https:\/\/www.omim.org\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0092-8674(95)90368-2","article-title":"Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A","volume":"81","author":"Richard","year":"1995","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1093\/brain\/aww133","article-title":"A heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy","volume":"139","author":"Vissing","year":"2016","journal-title":"Brain"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Lasa-Elgarresta, J., Mosqueira-Mart\u00edn, L., Naldaiz-Gastesi, N., S\u00e1enz, A., de Munain, A.L., and Vallejo-Illarramendi, A. (2019). Calcium Mechanisms in Limb-Girdle Muscular Dystrophy with CAPN3 Mutations. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184548"},{"key":"ref_6","unstructured":"(2021, May 04). Calpainopathy-GeneReviews\u00ae-NCBI Bookshelf, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1313\/#lgmd2a.Molecular_Genetics."},{"key":"ref_7","unstructured":"(2020, October 10). The CAPN3 gene homepage\u2014Global Variome shared LOVD. Available online: https:\/\/databases.lovd.nl\/shared\/genes\/CAPN3."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20106","DOI":"10.1016\/S0021-9258(19)47225-6","article-title":"Molecular cloning of a novel mammalian calcium-dependent protease distinct from both m- and \u03bc-types. Specific expression of the mRNA in skeletal muscle","volume":"264","author":"Sorimachi","year":"1989","journal-title":"J. Biol. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jmb.2011.01.057","article-title":"Non-proteolytic functions of calpain-3 in sarcoplasmic reticulum in skeletal muscles","volume":"407","author":"Ojima","year":"2011","journal-title":"J. Mol. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Toral-Ojeda, I., Aldanondo, G., Lasa-Elgarresta, J., Lasa-Fernandez, H., Vesga-Castro, C., Mouly, V., de Munain, A.L., and Vallejo-Illarramendi, A. (2018). A Novel Functional In Vitro Model that Recapitulates Human Muscle Disorders. Muscle Cell and Tissue-Current Status of Research Field, InTech.","DOI":"10.5772\/intechopen.75903"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1093\/hmg\/dds144","article-title":"Impaired calcium calmodulin kinase signaling and muscle adaptation response in the absence of calpain 3","volume":"21","author":"Kramerova","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00424-015-1747-8","article-title":"Calpain-3-mediated regulation of the Na+-Ca2+ exchanger isoform 3","volume":"468","author":"Michel","year":"2016","journal-title":"Pflugers Arch. Eur. J. Physiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"22986","DOI":"10.1074\/jbc.M110.126946","article-title":"Skeletal muscle-specific calpain is an intracellular Na+- dependent protease","volume":"285","author":"Ono","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.biochi.2015.09.010","article-title":"An eccentric calpain, CAPN3\/p94\/calpain-3","volume":"122","author":"Ono","year":"2016","journal-title":"Biochimie"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.nmd.2008.08.005","article-title":"Calpain 3, the \u201cgatekeeper\u201d of proper sarcomere assembly, turnover and maintenance","volume":"18","author":"Beckmann","year":"2008","journal-title":"Neuromuscul. Disord."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10593","DOI":"10.1016\/S0021-9258(18)82240-2","article-title":"Muscle-specific calpain, p94, is degraded by autolysis immediately after translation, resulting in disappearance from muscle","volume":"268","author":"Sorimachi","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.ejhg.5200888","article-title":"Clinical variability in calpainopathy: What makes the difference?","volume":"10","author":"Vainzof","year":"2002","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_18","first-page":"54","article-title":"Phenotypic variability in siblings with calpainopathy (LGMD2A)","volume":"27","author":"Schessl","year":"2008","journal-title":"Acta Myol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1590\/0004-282X20150168","article-title":"Limb-girdle muscular dystrophy type 2A in Brazilian children","volume":"73","author":"Zanoteli","year":"2015","journal-title":"Arq. Neuropsiquiatr."},{"key":"ref_20","unstructured":"(2020, October 12). Weekly Steroids in Muscular Dystrophy-Full Text View-ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04054375."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/mus.10319","article-title":"Early prednisone treatment in Duchenne muscular dystrophy","volume":"27","author":"Merlini","year":"2003","journal-title":"Muscle Nerve"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0960-8966(91)90099-E","article-title":"Steroids in duchenne muscular dystrophy\u2014Deflazacort trial","volume":"1","author":"Mesa","year":"1991","journal-title":"Neuromuscul. Disord."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2613.2006.00470.x","article-title":"The effects of glucocorticoid therapy on the inflammatory and Dendritic cells in muscular dystrophies","volume":"87","author":"Hussein","year":"2006","journal-title":"Int. J. Exp. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0960-8966(01)00198-5","article-title":"Do immune cells promote the pathology of dystrophin-deficient myopathies?","volume":"11","author":"Spencer","year":"2001","journal-title":"Neuromuscul. Disord."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.nmd.2004.02.011","article-title":"Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans","volume":"14","author":"Gaud","year":"2004","journal-title":"Neuromuscul. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.21338","article-title":"A phase I\/II trial of MYO-029 in adult subjects with muscular dystrophy","volume":"63","author":"Wagner","year":"2008","journal-title":"Ann. Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/sj.gt.3302928","article-title":"AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not \u03b1-sarcoglycan deficiency","volume":"14","author":"Bartoli","year":"2007","journal-title":"Gene Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1113\/JP279943","article-title":"Myostatin inhibition promotes fast fibre hypertrophy but causes loss of AMP-activated protein kinase signalling and poor exercise tolerance in a model of limb-girdle muscular dystrophy R1\/2A","volume":"598","author":"Kramerova","year":"2020","journal-title":"J. Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17987\/jcsm-cr.v2i1.37","article-title":"Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy","volume":"2","author":"Saitoh","year":"2017","journal-title":"JCSM Clin. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01486-4","article-title":"Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches","volume":"8","author":"Mariot","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/CIRCULATIONAHA.113.001340","article-title":"Restriction of calpain3 expression to the skeletal muscle prevents cardiac toxicity and corrects pathology in a murine model of limb-girdle muscular dystrophy","volume":"128","author":"Roudaut","year":"2013","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13395-017-0146-6","article-title":"Impaired regeneration in calpain-3 null muscle is associated with perturbations in mTORC1 signaling and defective mitochondrial biogenesis","volume":"7","author":"Yalvac","year":"2017","journal-title":"Skelet. Muscle"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ymthe.2005.09.017","article-title":"Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy Type 2A","volume":"13","author":"Bartoli","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Lostal, W., Roudaut, C., Faivre, M., Charton, K., Suel, L., Bourg, N., Best, H., Smith, J.E., Gohlke, J., and Corre, G. (2019). Titin splicing regulates cardiotoxicity associated with calpain 3 gene therapy for limb-girdle muscular dystrophy type 2A. Sci. Transl. Med., 11.","DOI":"10.1126\/scitranslmed.aat6072"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1089\/hum.2019.006","article-title":"Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb Infusion","volume":"30","author":"Mendell","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/mt.2013.246","article-title":"Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin \u03b12 surrogates","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_37","unstructured":"(2020, October 16). 1135\u2014Biopotency and Biodistribution\/ Toxicology Studies Following Systemic Gene Therapy with AAVrh74.tMCK.hCAPN3 in the Mouse Model for LGMD2A-ASGCT 23rd Annual Meeting. Available online: https:\/\/cslide-us.ctimeetingtech.com\/asgct23\/attendee\/eposter\/poster\/466."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Jaka, O., Casas-Fraile, L., Azpitarte, M., Aiastui, A., L\u00f3pez de Munain, A., and S\u00e1enz, A. (2017). FRZB and melusin, overexpressed in LGMD2A, regulate integrin \u03b21D isoform replacement altering myoblast fusion and the integrin-signalling pathway. Expert Rev. Mol. Med., 19.","DOI":"10.1017\/erm.2017.3"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"8437","DOI":"10.1128\/MCB.01296-06","article-title":"Regulation of the M-Cadherin-\u03b2-Catenin Complex by Calpain 3 during Terminal Stages of Myogenic Differentiation","volume":"26","author":"Kramerova","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/anie.200462552","article-title":"A small-molecule agonist of the Wnt signaling pathway","volume":"44","author":"Liu","year":"2005","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1471-4159.2008.05537.x","article-title":"Activation of \u03b2-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells","volume":"106","author":"Lim","year":"2008","journal-title":"J. Neurochem."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Liu, J., Campagna, J., John, V., Damoiseaux, R., Mokhonova, E., Becerra, D., Meng, H., McNally, E.M., Pyle, A.D., and Kramerova, I. (2020). A Small-Molecule Approach to Restore a Slow-Oxidative Phenotype and Defective CaMKII\u03b2 Signaling in Limb Girdle Muscular Dystrophy. Cell Rep. Med., 1.","DOI":"10.1016\/j.xcrm.2020.100122"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1532\/LH96.10010","article-title":"Review: Stem cells and gene therapy","volume":"16","author":"Alenzi","year":"2010","journal-title":"Lab. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.ymthe.2019.08.011","article-title":"Gene Correction of LGMD2A Patient-Specific iPSCs for the Development of Targeted Autologous Cell Therapy","volume":"27","author":"Selvaraj","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9613258","DOI":"10.1155\/2019\/9613258","article-title":"The Application of Induced Pluripotent Stem Cells in Pathogenesis Study and Gene Therapy for Vascular Disorders: Current Progress and Future Challenges","volume":"2019","author":"Peng","year":"2019","journal-title":"Stem Cells Int."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Nilsson, M.I., Macneil, L.G., Kitaoka, Y., Alqarni, F., Suri, R., Akhtar, M., Haikalis, M.E., Dhaliwal, P., Saeed, M., and Tarnopolsky, M.A. (2014). Redox state and mitochondrial respiratory chain function in skeletal muscle of LGMD2A patients. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0102549"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1093\/hmg\/ddp257","article-title":"Mitochondrial abnormalities, energy deficit and oxidative stress are features of calpain 3 deficiency in skeletal muscle","volume":"18","author":"Kramerova","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3233\/JND-150119","article-title":"Mammalian Mss51 is a Skeletal Muscle-Specific Gene Modulating Cellular Metabolism","volume":"2","author":"Moyer","year":"2015","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_50","unstructured":"(2020, October 16). Research\u2013Coalition to Cure Calpain 3. Available online: https:\/\/www.curecalpain3.org\/research\/."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/nan.12034","article-title":"Muscle atrophy in Limb Girdle Muscular Dystrophy 2A: A morphometric and molecular study","volume":"39","author":"Fanin","year":"2013","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_52","unstructured":"(2021, February 06). CAPN3 Protein (Human)-STRING \u0130nteraction Network. Available online: https:\/\/string-db.org\/network\/9606.ENSP00000380349."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1248\/bpb.b17-00342","article-title":"ER stress and disease: Toward prevention and treatment","volume":"40","author":"Kaneko","year":"2017","journal-title":"Biol. Pharm. Bull."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"25935","DOI":"10.1074\/jbc.R400008200","article-title":"Signaling the unfolded protein response from the endoplasmic reticulum","volume":"279","author":"Zhang","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1089\/ars.2007.1817","article-title":"ERADicate ER stress or die trying","volume":"9","author":"Kincaid","year":"2007","journal-title":"Antioxid. Redox Signal."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Toral-Ojeda, I., Aldanondo, G., Lasa-Elgarresta, J., Lasa-Fern\u00e1ndez, H., Fern\u00e1ndez-Torr\u00f3n, R., De Munain, A.L., and Vallejo-Illarramendi, A. (2016). Calpain 3 deficiency affects SERCA expression and function in the skeletal muscle. Expert Rev. Mol. Med., 18.","DOI":"10.1017\/erm.2016.9"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrm2199","article-title":"Signal integration in the endoplasmic reticulum unfolded protein response","volume":"8","author":"Ron","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.semcdb.2007.09.003","article-title":"The endoplasmic reticulum and the unfolded protein response","volume":"18","author":"Malhotra","year":"2007","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s12035-014-9029-6","article-title":"Crosstalk Between Endoplasmic Reticulum Stress, Oxidative Stress, and Autophagy: Potential Therapeutic Targets for Acute CNS Injuries","volume":"53","author":"Nakka","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1152\/physrev.00015.2006","article-title":"Endoplasmic reticulum stress signaling in disease","volume":"86","author":"Marciniak","year":"2006","journal-title":"Physiol. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.arr.2009.03.001","article-title":"ER and aging-Protein folding and the ER stress response","volume":"8","author":"Naidoo","year":"2009","journal-title":"Ageing Res. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.phrs.2017.02.018","article-title":"Unraveling the role of ER stress inhibitors in the context of metabolic diseases","volume":"119","author":"Sarvani","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/aps.2015.145","article-title":"Endoplasmic reticulum stress: A novel mechanism and therapeutic target for cardiovascular diseases","volume":"37","author":"Liu","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10557-018-6844-4","article-title":"The Role of Tauroursodeoxycholic Acid on Dedifferentiation of Vascular Smooth Muscle Cells by Modulation of Endoplasmic Reticulum Stress and as an Oral Drug Inhibiting In-Stent Restenosis","volume":"33","author":"Luo","year":"2019","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"C583","DOI":"10.1152\/ajpcell.00320.2016","article-title":"The unfolded protein response in relation to mitochondrial biogenesis in skeletal muscle cells","volume":"312","author":"Hood","year":"2017","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.4103\/1673-5374.169619","article-title":"All roads go to salubrinal: Endoplasmic reticulum stress, neuroprotection and glial scar formation","volume":"10","year":"2015","journal-title":"Neural Regen. Res."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Foltz, S.J., Luan, J., Call, J.A., Patel, A., Peissig, K.B., Fortunato, M.J., and Beedle, A.M. (2016). Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy. Skelet. Muscle, 6.","DOI":"10.1186\/s13395-016-0091-9"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1096\/fj.13-237388","article-title":"Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac function","volume":"28","author":"Bibee","year":"2014","journal-title":"FASEB J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.omtm.2019.05.011","article-title":"Rapamycin Rescues Age-Related Changes in Muscle-Derived Stem\/Progenitor Cells from Progeroid Mice","volume":"14","author":"Kawakami","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-642-41199-1_1","article-title":"Therapeutic potential of small molecules and engineered proteins","volume":"219","author":"Gurevich","year":"2014","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1074\/jbc.M115.705012","article-title":"Small molecular allosteric activator of the sarco\/endoplasmic reticulum Ca2+-ATPase (SERCA) attenuates diabetes and metabolic disorders","volume":"291","author":"Kang","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bmc.2016.10.008","article-title":"A new target for Parkinson\u2019s disease: Small molecule SERCA activator CDN1163 ameliorates dyskinesia in 6-OHDA-lesioned rats","volume":"25","author":"Dahl","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.aad4076","article-title":"Muscle physiology: A peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA activity in muscle","volume":"351","author":"Nelson","year":"2016","journal-title":"Science"}],"container-title":["Pathophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1873-149X\/28\/2\/16\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:03:34Z","timestamp":1760162614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1873-149X\/28\/2\/16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":73,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["pathophysiology28020016"],"URL":"https:\/\/doi.org\/10.3390\/pathophysiology28020016","relation":{},"ISSN":["1873-149X"],"issn-type":[{"value":"1873-149X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,18]]}}}